Bloom Energy stock price rebounds after 10% slide as CPI cools; Fed minutes next

February 13, 2026
Bloom Energy stock price rebounds after 10% slide as CPI cools; Fed minutes next

New York, February 13, 2026, 14:28 EST — Regular session

  • Bloom Energy picked up roughly 1.9% in the afternoon, recouping some ground after tumbling 10.6% on Thursday.
  • Choppy markets persisted as investors sifted through softer U.S. inflation numbers, leaving rate-cut bets very much alive.
  • Heading into a week shortened by the holiday, the stock is looking ahead to Fed minutes set for Feb. 18.

Bloom Energy Corporation clawed back 1.9% to trade at $141.61 Friday afternoon, regaining some ground after tumbling in the previous session. Shares changed hands between $131.05 and $144.54 during the day.

The fuel-cell maker now trades like a high-beta proxy for bets on AI-driven data centers and the electrification push. Shares flicker with rate chatter and mood swings in risk, headlines or not.

Thursday brought a sharp drop for Bloom. Shares slipped 10.6% to finish at $139.03, with trading volume topping 13 million, data from the company’s investor relations site showed.

Wall Street saw a broad selloff, tech stocks taking the hardest hits as traders held back ahead of coming U.S. inflation numbers.

Stocks in the U.S. climbed Friday, shaking off volatility following the inflation data, according to Reuters. Tech shares faced headwinds as fresh concerns over AI-related upheaval weighed on the sector, limiting broader market gains. Rate cut bets for June crept higher in Fed funds futures.

January’s consumer price index edged up 0.2%, marking a 2.4% gain over the past year—a touch softer than the 2.5% economists surveyed by Reuters had penciled in. “The inflation report is better than expected,” said Phil Orlando, chief market strategist at Federated Hermes. Reuters

Bloom, the maker of onsite fuel-cell power systems that don’t rely on combustion, put out a 2026 revenue target last week: it’s aiming for $3.1 billion to $3.3 billion. The company also sees non-GAAP earnings per share in the $1.33 to $1.48 range, stripping out certain costs. “Bring-your-own-power has shifted from a slogan to a business necessity,” founder and CEO KR Sridhar said Feb. 5. Bloom Energy

Some investors are flagging sizable orders from utilities as a sign of sustained demand. Back in January, American Electric Power’s subsidiary took up an option to purchase another 900 megawatts of Bloom’s solid oxide fuel cells—those generate electricity via a chemical process—in a deal pegged at roughly $2.65 billion. According to AEP, the new units are set for a facility near Cheyenne, Wyoming, with a 20-year offtake contract lined up with an undisclosed buyer.

Fuel-cell stocks moved up Friday, with FuelCell Energy climbing roughly 4.3%. Plug Power tacked on 5.2%.

Still, the risks run in both directions. With Bloom trading at high multiples and momentum strong, there’s not much room for error—shares could take a hit if Treasury yields climb again or if turning backlog into revenue slows down.

The macro calendar takes over from here. With U.S. markets shuttered Monday for Washington’s Birthday, investors face a shortened stretch: the Fed drops minutes from its January gathering on Feb. 18, and the Producer Price Index for January lands Feb. 27.

Stock Market Today

  • Australia Aspirin Market 2026-2035: Growth in Low-Dose Cardiovascular Segment amid Import Dependency
    May 23, 2026, 11:25 AM EDT. The Australia aspirin market is evolving, with low-dose (81 mg) formulations for cardiovascular prevention driving volume growth to 40-45% of unit sales by 2026. Private-label aspirin captures 25-30% of retail volume, pressuring branded producers amid a 50-60% price gap. The market depends on imports for over 90% of acetylsalicylic acid active pharmaceutical ingredient (API), mainly from China and India, exposing it to supply and cost volatility with input prices up 12-18% in 18 months. Aging demographics boost demand for prophylactic aspirin at 3-5% annual growth, outpacing traditional pain relief. Consumer trends favor coated and combination tablets now 20% of revenues. Online sales channels are expanding, making up 12-15% of volume. Challenges include regulatory costs, API price swings, stockouts, and retail consolidation squeezing supplier margins and innovation.